AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

Shots:

  • AstraZeneca to receive upfront, $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & associated brands (Acimax, Antra, Mepral, Mopral, Omepral and Zoltum) excluding the US, China, Japan & Mexico
  • The agreement allows AstraZeneca to focus on its three main therapeutic areas while it continues to manufacture, supply & commercialize the therapy where it holds the rights
  • Losec is a proton pump inhibitor, helps to reduce the amount of acid produced by the stomach in patients with GERD & ulcers

Click here to­ read full press release/ article | Ref: AstraZeneca| Image: China Daily